Clinical Edge Journal Scan

Predictors of 4 or more axillary lymph node metastases in clinically node-negative BC patients


 

Key clinical point: Certain preoperative clinicopathological factors can predict the presence of ≥4 pathologically positive lymph nodes in postmenopausal women with clinically node-negative (cN0) breast cancer (BC) who underwent sentinel lymph node biopsy (SLNB) with or without completion axillary lymph node dissection (cALND).

Major finding: Only 2.5% of the evaluated patients reported having ≥4 positive lymph nodes, with the factors serving as independent predictors of ≥4 positive nodes being larger tumor size (odds ratio [OR] 1.42; P < .0001), invasive lobular carcinoma (ILC) or mixed invasive ductal carcinoma/ILC histology (OR 3.03 or 1.99, respectively; P = .008), multifocality (OR 3.58; P < .0001), and the presence of lymphovascular invasion (OR 4.77; P < .0001).

Study details: This retrospective review included 2532 postmenopausal women with cN0 BC who underwent SLNB, of whom 24.3% underwent cALND.

Disclosures: This study was supported by an US National Institutes of Health/National Cancer Institute Cancer Center Support Grant. Some authors declared serving on medical or scientific advisory boards of, receiving research funding or support for clinical trials from, or having other ties with various sources.

Source: Farley C et al. To dissect or not to dissect: Can we predict the presence of four or more axillary lymph node metastases in postmenopausal women with clinically node-negative breast cancer? Ann Surg Oncol. 2023 (Sep 5). doi: 10.1245/s10434-023-14245-1

Recommended Reading

Breast cancer: Hope in sight for improved tamoxifen therapy?
Breast Cancer ICYMI
Commentary: Alcohol, PPI use, BMI, and lymph node dissection in BC, September 2023
Breast Cancer ICYMI
Do AI chatbots give reliable answers on cancer? Yes and no
Breast Cancer ICYMI
Sacituzumab govitecan reduces mortality in pretreated HR+/HER2− metastatic BC
Breast Cancer ICYMI
Chemotherapy-free anti-ERBB2 strategy may be a first-line treatment option in ERBB2+ metastatic BC
Breast Cancer ICYMI
Adding ovarian suppression to adjuvant tamoxifen is beneficial for women with existing ovarian function and ER+ BC
Breast Cancer ICYMI
Adjuvant capecitabine plus ibandronate combination fails in phase 3 study
Breast Cancer ICYMI
HER2+ metastatic BC with brain metastasis: Pyrotinib shows long-term meaningful outcomes in real world
Breast Cancer ICYMI
Home-based exercise and nutritional intervention may benefit patients with newly diagnosed BC
Breast Cancer ICYMI
Surgical complications likely in obese patients undergoing mastectomy with immediate reconstruction
Breast Cancer ICYMI